Chelsie Derman is an assistant editor for HCPLive who covers psychiatry, sleep medicine, and geriatrics. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.
She can be reached at cderman@mjhlifesciences.com
Quality of Life Is Worse for Patients with Heart Failure than Many Cancers, Study Finds
November 12th 2023Participants with heart failure measured lower on physical and mental component scores than patients with lung, colon, breast, or prostate cancer, highlighting their worser health-related quality of life.
Read More
Presented at AAO 2023, Kendra Klein-Mascia, MD, discussed her team’s study, comparing faricimab with aflibercept. The study found 2 injections of faricimab gets rid of 75% of retina fluid by week 8, but for aflibercept, erasing the same amount of fluid takes 3 injections until week 12.
Read More
Study Explores High Prevalence of Anemia in Children Under 5 Years Old in Ghana
November 9th 2023Investigators studied factors that could be associated with anemia in children < 5 years old, such as gender, age in years, type of birth (single or multiple), birth order, preceding birth interval in months (<18 months, 18+ months, or 1st born), and fever or no fever in the past 2 weeks (with malaria and without). Other factors related to mother or caregiver characteristics and household characteristics.
Read More
Research Shows Low Dose Atropine Links to Slowing Myopia Progression in Children
November 5th 2023Two studies presented at AAO demonstrate that low dose atropine is associated with slowing myopia progression, but another study finds that this is not true. Thus, there are mixed results on this relationship.
Read More
Study Indicates When Geographic Atrophy Will Reach Fovea
November 3rd 2023Without treatment, lesions > 500 µm away from the fovea will take anywhere from 3.07 years to 12.9 years to reach it. With pegcetacoplan treatment, the lesion will reach the fovea anywhere between 3.56 years – 15 years for monthly treatment and 3.47-14.6 years for treatment every other month.
Read More
Clinical Trials for Biosimilars Could Be Shortened, Study Finds
October 31st 2023A new study indicates biosimilar trials remained consistent from 4-6 months through 12 months, which investigators suggest indicates these trials could be shortened without affecting safety and efficacy profiles.
Read More